IRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
IRadimed Corp (IRMD) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive analyst sentiment, and a solid growth trajectory. While technical indicators are neutral, the company's consistent revenue growth, profitability, and new product launches make it a compelling long-term investment opportunity.
The technical indicators for IRMD show a neutral to slightly bullish trend. The MACD histogram is positive at 0.136, indicating bullish momentum, though it is contracting. RSI is neutral at 51.682, suggesting no overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 99.852, with key resistance at 105.418 and support at 94.286.
Record revenue of $22.7 million in Q4 2025, marking the 18th consecutive quarter of record revenue.
Non-GAAP net income of $7 million, exceeding expectations.
Launch of the 3870 intravenous infusion pump, contributing to sales growth.
Increased quarterly dividend from $0.17 to $0.20 per share.
Positive analyst sentiment with price targets raised to $120 by both Lake Street and Roth Capital.
Gross margin declined slightly to 75.06%, down 1.41% YoY.
Cash flow from operations decreased by 2% YoY in Q4
Stock trend analysis indicates a 60% chance of a slight decline (-1.31%) in the next day.
IRadimed Corp reported strong financial performance in Q4 2025. Revenue increased by 17.03% YoY to $22.69 million, net income rose by 25.17% YoY to $6.44 million, and EPS grew by 25% YoY to $0.50. However, gross margin slightly declined to 75.06%, and cash flow from operations dropped by 2% YoY.
Analysts are bullish on IRMD. Lake Street and Roth Capital both raised their price targets to $120, citing strong Q4 results, improved forward estimates, and confidence in the company's growth trajectory. Analysts believe the 3870 pump launch will drive further upside.
